Over the course of the operation, authorities said they seized 400 grams of powdered cocaine; three AR-15-style assault rifles; multiple magazines and assorted ammunition; scales and drug packaging ...

The Food and Drug Administration has approved Celltrion’s Omlyclo (omalizumab-igec) as a biosimilar designated as interchangeable with Xolair (omalizumab) for the treatment of moderate to severe ...

(Reuters/Eloisa Lopez) MANILA — Former Philippine President Rodrigo Duterte was arrested and taken into custody on Tuesday in Manila on an International Criminal Court warrant for the “war on drugs” ...

FINAL TOLL By the time Duterte left office in 2022, the drug war's official toll had at least tripled. Police said 6,200 suspects were killed during anti-drug operations. The Philippine government ...

If I make it to the presidential palace, I will do just what I did as mayor. You drug pushers, hold-up men and do-nothings, you better go out. Because I'd kill you," he said during that campaign.

Biotechnology firm Biocon Ltd on Friday (March 7) said its subsidiary Biocon Biologics Ltd has announced positive results from its phase 3 clinical trial for Yesintek, a biosimilar to ustekinumab ...

On Friday, the US Food and Drug Administration (FDA) approved as the first interchangeable biosimilar to Swiss pharma giant Roche's (ROG: SIX) anti-IgE monoclonal antibody Xolair (omalizumab). The FDA ...

Omlyclo is the first interchangeable biosimilar to omalizumab (Xolair; Genentech, Novartis). Omlyclo was approved to treat the same conditions as Xolair. The FDA approved Celltrion’s omalizumab ...

Celltrion's Omlyclo (omalizumab-igec) is the first omalizumab biosimilar to be approved for US patients, and it was approved with interchangeability, making it easier for patients to switch to the ...

The products are expected to be available in June 2025. The US Food and Drug Administration (FDA) has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt ...

Biosimilar competition has a demonstrated record of generating significant systemic savings while still incentivizing continued drug innovation. Adjusted for inflation, the average prices for ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy.